Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę "Anderson, John" wg kryterium: Autor


Tytuł:
A new triadotypid insect from the Late Triassic of South Africa
Autorzy:
DEREGNAUCOURT, ISABELLE
WAPPLER, TORSTEN
ANDERSON, JOHN M.
BÉTHOUX, OLIVIER
Tematy:
arthropoda
odonata
pandiscoidalia
triassic
carnian
molteno formation
south africa
Pokaż więcej
Wydawca:
Polska Akademia Nauk. Instytut Paleobiologii PAN
Powiązania:
https://bibliotekanauki.pl/articles/945629.pdf  Link otwiera się w nowym oknie
Opis:
Extant odonates (damsel- and dragonflies) represent a small subset of the historical biodiversity of this group. Among their successive stem-groups, the Triadotypomorpha are poorly documented. Herein we describe a new species Reisia rieki from the Molteno Formation (South Africa, Upper Triassic) belonging to this taxon. The comparatively large sample allows a relatively complete description of the wing venation in Triadotypomorpha. We noticed the occurrence of a strongly oblique crossvein located between RA and RP1, a condition documented in some other Pandiscoidalia and which might be of phylogenetic importance. The new species probably inhabited open landscapes and foraged above large water bodies. The documentation of a Gondwanian Triadotypomorpha demonstrates that the group had a worldwide distribution by the Triassic.
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Dinutuximab Beta versus naxitamab in the treatment of relapsed/refractory neuroblastoma in patients with stable disease, minor response or partial response and disease in bone or bone marrow : systematic review and matching-adjusted indirect comparison
Autorzy:
Manzitti, Carla
Luksch, Roberto
Lode, Holger N.
Wieczorek, Aleksandra
Holko, Przemysław
Gray, Juliet
Anderson, John
Śladowska, Katarzyna
Ebeling, Torsten
Yaniv, Isaac
Canete, Adela
Ash, Shifra
Troschke-Meurer, Sascha
Ladenstein, Ruth L.
Valteau-Couanet, Dominique
Garaventa, Alberto
Kawalec, Paweł
Siebert, Nikolai
Opis:
Objective: Dinutuximab beta (DB) and naxitamab (NAXI) with GM-CSF are used for maintenance treatment of relapsed/refractory neuroblastoma. The objective of this study was to systematically assess comparative efficacy of the two therapies within their designated indications in accordance with established clinical guidelines. Methods: Relevant evidence was identified in systematic literature review. Individual patient data (IPD) from prospective clinical trials of DB were assessed and data on patients with disease in bone or bone marrow, as assessed in MRI, CT, mIBG or biopsy, with incomplete response to previous therapy were included. Patients with complete response, progressive disease and/or soft tissue disease were excluded. DB population was adjusted for sex, MYCN amplification, disease type (relapsed, refractory), and disease site (bone marrow and/or bone) to balance aggregated characteristics of NAXI population. More characteristics were included in sensitivity analyses, including DB treatment without interleukin-2, as currently recommended. Overall response rate (ORR) was assessed as best response. Results: Aggregated data for NAXI from Study 201 (n = 52) and Study 230 (n = 38) and IPD from DB studies (APN311-202, APN311-304, c = 77) met the inclusion criteria. Compared to NAXI, DB significantly extended progression-free survival (PFS): hazard ratio, DB vs. NAXI of 0.47 (95% CI: 0.26 to 0.87, p = 0.015). ORR was 60.1% (95% CI: 48.5% to 71.6%) for DB vs. 43.3% (33.1% to 53.6%) for NAXI (ORR odds ratio, DB vs. NAXI was 1.97, 95% CI: 1.02 to 3.80, p = 0.044). Sensitivity analyses and unadjusted comparisons supported the results. Conclusion: In the indirect comparison, dinutuximab beta significantly extended PFS and increased ORR compared to naxitamab.
Dostawca treści:
Repozytorium Uniwersytetu Jagiellońskiego
Artykuł

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies